metabolic disease

Photo
08.11.2024 • News

Ascendis Licences Proprietary Technology to Novo Nordisk

Danish biopharma company Ascendis Pharma will grant pharmaceutical giant Novo Nordisk an exclusive worldwide license to its TransCon technology platform to develop, manufacture, and commercialize proprietary products for the treatment of metabolic and cardiovascular diseases.

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.